Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Sells 30 More Genome Analyzers to Broad Institute

NEW YORK (GenomeWeb News) – Illumina said today that the Broad Institute of MIT and Harvard has purchased 30 of the company's Genome Analyzers, increasing the institute's total installed base of Illumina systems to 89.

Robert Nicol, director of sequencing operations at Broad, said in a statement that the institute purchased the additional instruments to ramp up its sequencing capabilities in whole genome, whole exome, and whole transcriptome analysis.

"We are happy with the technology’s accuracy, ease of use, and scalability, as well as continued system improvements that have recently enabled us to generate multiple runs with more than 50 gigabases of high-quality sequence data," Nicol said.

Financial terms of the deal were not disclosed.

In addition, Illumina today reaffirmed its revenue guidance of a minimum of $165 million for the fourth quarter of 2009.

Last week, Illumina reported that its third-quarter revenues rose 5 percent. However, the company's Q3 revenues were about $4 million below the low end of its guidance and missed analysts' consensus estimate for the quarter, which the company blamed on a sequencing reagent quality issue.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.